CClinicalTrials.gg
RecruitingNCT06248892Updated Mar 12, 2024

The Effect of Oral and Nasal Feeding on Cerebral Small Vessel Disease

An interventional study of Nasogastric Tube Feeding and Intermittent Oro-esophageal Tube Feeding in Cerebral Small Vessel Diseases, sponsored by Zeng Changhao. Recruiting at 1 site in Thailand. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Zeng Changhao · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

Nasogastric tube feeding (NGT) has been widely used in cerebral small vessel disease (CSVD) patients with dysphagia but has a significant risk of complications. Intermittent Oro-esophageal Tube Feeding (IOE) is an established enteral nutrition approach that can be used with comprehensive rehabilitation therapy. This study aims to explore the clinical effect of IOE vs. NGT on CSVD Patients with Dysphagia. Compared to NGT, IOE, as an enteral nutrition support mode, in CSVD Patients with Dysphagia who received comprehensive rehabilitation therapy, showed advantages in improvement in dysphagia, nutritional status, ADL, QOL, pneumonia, and adverse events, which should be considered as the preferred approach.

Read the detailed description

Nasogastric tube feeding (NGT) has been widely used in cerebral small vessel disease (CSVD) patients with dysphagia but has a significant risk of complications. Intermittent Oro-esophageal Tube Feeding (IOE) is an established enteral nutrition approach that can be used with comprehensive rehabilitation therapy. This study aims to explore the clinical effect of IOE vs. NGT on CSVD Patients with Dysphagia.

This was a randomized controlled study with 60 CSVD Patients with Dysphagia who received comprehensive rehabilitation therapy. Patients enrolled were randomly divided into the observation group (with IOE, n=30) and the control group (with NGT, n=30). At admission and after treatment, Video Fluoroscopic Swallowing Study (VFSS) and Functional Oral Intake Scale (FOIS), body mass index (BMI), serum albumin (Alb), and hemoglobin (Hb), Modified Barthel Index (MBI) and World Health Organization Quality of Life Assessment Instrument Brief Version (WHOQOL-BREF) were recruited to assess and compare dysphagia, nutritional status, activities of daily living (ADL) and quality of life (QOL). The incidence of pneumonia was recorded and compared.

02

Conditions studied

  • Cerebral Small Vessel Diseases
03

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinical diagnosis of Cerebral Small Vessel Disease;
  • Must be able to cooperate with treatment and questionnaire investigation, (Generally with a Mini-Mental State Examination (MMSE) score ≥ 24) ;
  • Clinical diagnosis of dysphagia through the Functional Oral Intake Scale (FOIS) and Video Fluoroscopic Swallowing Study (VFSS);
  • Age between 40 and 70 years;
  • Enteral nutrition support was required and feasible.
  • No history of prior stroke.

Exclusion criteria

Exclusion Criteria:

  • Dysphagia related to other cerebrovascular diseases or caused by neurodegenerative diseases;
  • Complicated with severe liver and kidney failure, tumors, or hematological disorders;
  • Simultaneously need to undergo other therapy that might affect the outcomes of this study;
  • Pregnant or nursing females.
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    The observation group

    Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy. Besides, the observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the relevant guidelines.

    Device: Intermittent Oro-esophageal Tube Feeding · Behavioral: comprehensive rehabilitation therapy

  • Active comparator
    The control group

    Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy. Besides, the control group was given enteral nutritional support with nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation.

    Device: Nasogastric Tube Feeding · Behavioral: comprehensive rehabilitation therapy

Interventions

  • DeviceNasogastric Tube Feeding

    Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.

  • DeviceIntermittent Oro-esophageal Tube Feeding

    The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.

  • Behavioralcomprehensive rehabilitation therapy

    Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.

05

What researchers measure

Primary outcomes

  1. Video Fluoroscopic Swallowing Study

    Video Fluoroscopic Swallowing Study, which is considered as the "gold standard", swallowing process is divided into four periods: cognitive, oral, pharyngeal, and esophageal periods with a total score of 10 and a higher score indicates better swallowing ability (less dysphagia).

    Time frame: day 1 and day 15

Secondary outcomes

  1. Functional Oral Intake Scale

    During Dysphagia-Functional Oral Intake Scale assessment, evaluators engage in communication with the patient, conduct observations, and make records to assess the patient's oral intake ability. The FOIS assessment form includes seven levels of scoring, ranging from level 1 to level 7, indicating a progressive improvement in the patient's oral intake ability. In general, the result below level 6 indicates unsafe for oral intake while level 6 and above indicates that eating via mouth can be safely conducted.

    Time frame: day 1 and day 15

  2. Body mass index

    Weight and height will be combined to report Body mass index in kg/m\^2

    Time frame: day 1 and day 15

  3. Serum albumin

    Serum albumin was recorded via blood routine test.(Alb, g/L)

    Time frame: day 1 and day 15

  4. Hemoglobin

    Hemoglobin was recorded via blood routine test.(Hb, mg/L)

    Time frame: day 1 and day 15

  5. Pneumonia

    The occurrence of pneumonia in patients was assessed before and after treatment. Specifically, first of all, the symptom assessment and physical examination were conducted to all patients, during which, the doctor would inquire symptoms related to pneumonia, such as cough, sputum production, difficulty breathing, chest pain, etc. and observe the patient's respiratory condition, including respiratory rate, breath sounds, and any abnormal signs in the chest. If there was probability for potential pneumonia, patients were requested for further diagnosis

    Time frame: day 1 and day 15

  6. Activities of daily living

    The activities of daily living was assessed utilizing the Modified Barthel Index (MBI). Modified Barthel Index includes the following 10 subscales. For each subscale, choices encoded with the score 10, 8, 5, 2, 0 are set with the decreasing level of self-dependence, while the final total is positively correlated with Activities of daily living. Cronbach's α of questionnaire adopted is 0.916.

    Time frame: day 1 and day 15

  7. World Health Organization Quality of Life Assessment Instrument Brief Version

    The Quality of Life was assessed utilizing the World Health Organization Quality of Life Assessment Instrument Brief Version (WHOQOL-BREF). WHOQOL-BREF covers various aspects such as mobility, pain, emotions, personal relationships, living conditions, and access to health services, to evaluate Quality of Life. Each item is rated on a Likert scale, and the scores are transformed into a standardized score ranging from 0 to 100, with higher scores indicating better Quality of Life

    Time frame: day 1 and day 15

06

Study locations

1 of 1 sites recruiting
  • Ratchaburi Center Hos.
    Ratchaburi, Thailand
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06248892
Lead sponsor
Zeng Changhao
Responsible party
Zeng Changhao (Research Director, People's Hospital of Zhengzhou University) — Sponsor-investigator
First posted
Feb 8, 2024
Start date
Feb 15, 2024
Primary completion
Apr 2024 (estimated)
Completion
May 2024 (estimated)
Last update
Mar 12, 2024

Study contacts

Zhefeng Wang, Master
Contact
zhengzhouzhj@qq.com
19501376864
Weijia Zhao, Master
Contact
zwjww2009@163.com
17839973473
Nieto Luis, Master
principal investigator · Site Coordinator of United Medical Group located in Miami

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion